No Record Found
Sector
PharmaceuticalsOpen
₹97.99Prev. Close
₹95.24Turnover(Lac.)
₹5.3Day's High
₹97.99Day's Low
₹95.4152 Week's High
₹348.4552 Week's Low
₹81.01Book Value
₹83.14Face Value
₹10Mkt Cap (₹ Cr.)
118.97P/E
8.28EPS
11.5Divi. Yield
029 Aug 2025
12:00 AM
AGM
Announcement Date: 29 Aug, 2025
20 Jan 2025
12:00 AM
EGM
20 Aug 2025
12:00 AM
Board Meeting
Agenda : Audited Result
No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 12.3 | 12.3 | 12.3 | 12.3 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 86.67 | 73.33 | 58.93 | 47.57 |
Net Worth | 98.97 | 85.63 | 71.23 | 59.87 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 |
|---|---|---|---|
Revenue | 60.75 | 55.84 | 48.76 |
yoy growth (%) | 8.77 | 14.52 | |
Raw materials | -21.87 | -23.65 | -21.06 |
As % of sales | 36.01 | 42.35 | 43.2 |
Employee costs | -3.97 | -4.11 | -3.18 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 |
|---|---|---|---|
Profit before tax | 12.74 | 5.99 | 3.26 |
Depreciation | -2.81 | -2.76 | -2.81 |
Tax paid | -3.11 | -1.22 | -1.51 |
Working capital | 14.37 | 10.27 | |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 |
|---|---|---|---|
Growth matrix (%) | |||
Revenue growth | 8.77 | 14.52 | |
Op profit growth | 69.47 | 10.59 | |
EBIT growth | 97.21 | 17.67 | |
Net profit growth | 143.67 | 171.62 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,716.1 | 88.09 | 4,11,737.88 | 564.22 | 0.93 | 4,511.27 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,539.5 | 69 | 1,73,459.82 | 696 | 0.46 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,825.8 | 60.67 | 1,29,469.87 | 597 | 0.16 | 2,707 | 249.83 |
Cipla Ltd CIPLA | 1,514.9 | 23.54 | 1,22,361.18 | 1,210.53 | 1.06 | 4,495.16 | 411.56 |
Dr Reddys Laboratories Ltd DRREDDY | 1,211.5 | 18.73 | 1,01,100.94 | 387.3 | 0.66 | 4,602.9 | 377.57 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
FALGUN VALLABHBHAI SAVANI
Executive Director & Chief Executive Officer
JIGNESHBHAI VALLABHBHAI SAVANI
Independent Director
Krishna Mitulbhai Shah
Independent Director
Kajal Chintanbhai Vaghani
Independent Director
Pravin Manjibhai Bhayani
Independent Director
Bintal Bhaveshkumar Shah
Company Sec. & Compli. Officer
Sanket Bhupendrabhai Trivedi
805 Dwarkesh Complex,
RC Dutt Road Alkapuri,
Gujarat - 390007
Tel: 91-265-2332018
Website: http://www.pardrugs.com
Email: cs.sanket@pardrugs.com
5th Floor 506 to 508,
ABC-I Off C G Road, Navrangpura,
Ahmedabad-380009
Tel: 91-79-26465179
Website: https://in.mpms.mufg.com/
Email: ipo.team@linkintime.co.in
Summary
Par Drugs and Chemicals Limited was originally incorporated as a Private Limited Company with the name Par Drugs and Chemicals Private Limited at Bhavnagar, Gujarat. On 26 February 1999. Subsequently,...
Read More
Reports by Par Drugs & Chemicals Ltd
What is the Par Drugs & Chemicals Ltd share price today?
What is the Market Cap of Par Drugs & Chemicals Ltd?
What is the PE and PB ratio of Par Drugs & Chemicals Ltd?
What is the 52 Week High and Low of Par Drugs & Chemicals Ltd?
What is the CAGR of Par Drugs & Chemicals Ltd?
What is the shareholding pattern of Par Drugs & Chemicals Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.